Format

Send to

Choose Destination
Fertil Steril. 2004 May;81(5):1357-65.

Preclinical evaluation of magainin-A as a contraceptive antimicrobial agent.

Author information

1
Immunology Laboratory, National Institute for Research in Reproductive Health, Parel, Mumbai, India.

Abstract

OBJECTIVE:

To evaluate the safety and contraceptive efficacy of magainin-A in monkeys.

DESIGN:

Controlled laboratory study.

SETTING:

Department of Immunology, National Institute for Research in Reproductive Health, Parel, Mumbai, India.

ANIMAL(S):

Male and female bonnet monkeys (Macaca radiata).

INTERVENTION(S):

Animals were treated intravaginally with 1 mg of magainin-A before attempted conception, as well as daily for 14 days to assess local and systemic toxicity.

MAIN OUTCOME MEASURE(S):

Suitability of magainin-A for the control of pregnancy and sexually transmitted infections.

RESULT(S):

Complete sperm immobilization was observed within 20 seconds after the exposure to magainin-A (800-1,000 microg) in vitro. Intravaginal administration of 1 mg of magainin-A blocked conception in monkeys. When magainin-A was administered intravaginally for 14 consecutive days, no treatment-related abnormalities were observed in menstrual cycle length, vaginal epithelial cell morphology, and hematologic/serum biochemical profiles. The peptide inhibited the growth of sexually transmitted infection-causing pathogens but not HIV-1 and HIV-2.

CONCLUSION(S):

Magainin-A can be used as an effective and safe intravaginal contraceptive compound with additional protection against sexually transmitted infection-causing pathogens.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center